Adaptive Biotechnologies Corporation Announces Translational Collaboration with Takeda
Thursday, April 13, 2023
Adaptive Biotechnologies Corporation announced it has entered into a translational collaboration with Takeda to use its clonoSEQ® Assay to assess minimal residual disease (MRD) to facilitate the development and commercialization of Takeda’s pipeline of treatments for patients with lymphoid malignancies.
This translational collaboration with Takeda incorporates the use of clonoSEQ Assay technology in clinical trials to support the clinical development of groundbreaking oncological therapies. MRD is an important measure of whether novel treatments are inducing effective and durable responses for patients, and its use as an endpoint is rapidly growing.
As part of the collaboration, MRD status based on Adaptive’s clonoSEQ Assay will be used as an endpoint in certain clinical trials to assess the depth and duration of response to Takeda’s investigational medicines in patients with lymphoid malignancies.
This multi-year agreement will cover existing and future programmes and adds to Adaptive’s growing list of translational collaborations with pharmaceutical companies. Adaptive will receive an upfront payment and will be eligible to receive milestone payments upon achievement of specific milestones in certain geographies.
